ZEGFROVY® (Sunvozertinib) Shows Antitumor Activity in 1L NSCLC Patients with EGFR PACC or Other Uncommon Mutations
Dr. Xiaolin Zhang, CEO of Dizal, said: “NSCLC patients with EGFR PACC and other uncommon mutations represent a population with substantial unmet medical need, given the limited availability of effective and well-tolerated target therapies, compared to those available for classical EGFR mutations. The data presented at ELCC further reinforces the potential of ZEGFROVY to address this gap. We are committed to advancing our clinical development programs, with the goal of bringing transformative treatment options to the global lung cancer community as quickly as possible.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.